Kahn R S, Asnis G M, Wetzler S, van Praag H M
Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY 10467.
Psychopharmacology (Berl). 1988;96(3):360-4. doi: 10.1007/BF00216062.
Normal controls (NC) (n = 15), patients with panic disorder (PD) (n = 13) and patients with major depression (MD) (n = 17) were challenged with a single, oral dose (0.25 mg/kg) of the selective 5HT agonist m-chlorophenyl-piperazine (MCPP) or placebo. Blood samples were assayed for cortisol and MCPP levels every 30 min. The PD group had an augmented cortisol release when compared to the other two groups. Finally, a significant correlation was found across all subjects between clinical anxiety level and cortisol release on MCPP. These data support the hypothesis of 5HT receptor hypersensitivity in PD.
正常对照组（NC）（n = 15）、惊恐障碍患者（PD）（n = 13）和重度抑郁症患者（MD）（n = 17）接受单次口服剂量（0.25 mg/kg）的选择性5-羟色胺（5HT）激动剂间氯苯哌嗪（MCPP）或安慰剂激发试验。每30分钟采集血样检测皮质醇和MCPP水平。与其他两组相比，PD组的皮质醇释放增加。最后，在所有受试者中发现临床焦虑水平与服用MCPP后的皮质醇释放之间存在显著相关性。这些数据支持了惊恐障碍中5HT受体超敏反应的假说。
